300 Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma

D.W. Rasco, M.R. Middleton, R. Gonzalez, P. Corrie, A. Pavlick, P. Lorigan, R. Plummer, M. Gore, C. Herbert, S.S. Agarwala, T.F. Logan, S.N. Khleif, K.P. Papadopoulos, L. Rangachari, A. Suri, Q. Xu, M. Kneissl, V. Bozón, A.J. Olszanski

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)S53-S54
Number of pages2
JournalEuropean Journal of Cancer
Volume51
DOIs
Publication statusPublished - Sept 2015

Cite this